Eris Lifesciences Ltd
ERIS
Company Profile
Business description
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
Contact
Ramdas Road
Plot No. 142/2, Shivarth Ambit
Off SBR, Near Swati Bungalows
Bodakdev
AhmedabadGJ380054
INDT: +91 7969661000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
3,558
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.40 | 22.00 | -0.24% |
| CAC 40 | 7,874.89 | 24.46 | 0.31% |
| DAX 40 | 24,465.87 | 225.05 | 0.93% |
| Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
| FTSE 100 | 9,109.50 | 48.01 | 0.53% |
| HKSE | 25,633.29 | 95.22 | 0.37% |
| NASDAQ | 21,020.02 | 127.33 | 0.61% |
| Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
| NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
| S&P 500 | 6,358.91 | 49.29 | 0.78% |
| S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
| SSE Composite Index | 3,605.73 | 23.43 | 0.65% |